Where to Spread Your Estrogen: Comparing Medical Evidence with Social Media Guidance

This article is adapted from "Buyer, Beware: The Estrogen Face Cream Trend Has a Data Problem," written by Dr. Sarah Berg.

A trend spreading across TikTok and Instagram tells women to apply their vaginal or systemic estrogen — prescriptions like Divigel and EstroGel, or a compounded cream sold specifically for the face — directly to their skin as an anti-aging treatment. No FDA-approved estrogen product is labeled for facial use. The single best-designed study on the subject excluded any woman already using hormone therapy, which describes most women trying this today. The newest study behind a branded face cream is funded and published by the company selling it, not independently peer-reviewed. And this isn't a new claim: the same pitch, in different packaging, has been sold to women since 1927.

The pattern shows up the same way across platforms: a woman warms a dab of her vaginal estrogen cream between two fingers and smooths it along her cheekbones like a serum, framing it as the thing her dermatologist won't tell her about. Some aren't reaching for a vaginal prescription at all — they're taking EstroGel or Divigel, gels formulated and FDA-approved for the arm or thigh, and applying that to the face instead. Divigel's own label states plainly that this isn't its intended use: do not apply to the face, breasts, or irritated skin. Nonetheless, the comment sections underneath these videos are full of women asking where to get a prescription, or whether a compounded, face-specific version being sold by a telehealth company is worth the markup.

What the medical evidence shows

Selfority reviewed the primary literature directly — the original studies, not how they've been summarized in captions and comment threads. What that review found was a handful of small studies, spanning three decades, testing different estrogens at different concentrations on different populations for different lengths of time, arriving at results that don't agree with each other.

The strongest data point is a 1994 trial published in Maturitas. Fifty-four postmenopausal women, none on any hormone therapy, applied actual Premarin cream — the FDA-approved vaginal estrogen product — to their faces nightly for twenty-four weeks in a real double-blind, placebo-controlled design. The result was a measurable increase in skin thickness and clinician-rated fine wrinkling compared to placebo. It is the best-designed study in the entire body of literature on this question, and the one cited most often. What's usually left out: the women themselves did not report a noticeable difference in how their skin looked. Their doctors saw a change under measurement; the women, living in their own faces every day, mostly didn't. And every one of the fifty-four women started the trial completely hormone-naive — a detail that rarely makes it into the version of this study that circulates online. The woman most likely to be trying this today, already on vaginal estrogen for genitourinary symptoms and now also applying it to her face, was excluded from this trial by design.

A 2014 study in Acta Dermato-Venereologica is the other one worth slowing down for, because it's where the "estrogen is estrogen" logic breaks down. Forty women, double-blind, vehicle-controlled, twenty-four weeks, cream applied specifically to crow's feet. This trial did not test estradiol, the estrogen actually in Vagifem, Imvexxy, Estrace, and Estring. It tested estrone, a different estrogen entirely, and found no improvement in wrinkles or elasticity — along with a tenfold increase in a marker called MMP-1, an enzyme that breaks collagen down rather than building it. The one rigorously controlled trial testing a form of estrogen other than estradiol found the opposite of a benefit.

Virtually no study has measured what happens when a woman already using estrogen — vaginally or systemically — adds a second, unmeasured daily application to her face.

The one study Selfority could locate on this specific question involved 15 women on a compounded estrogen cream, with no control group. Every trial that found any benefit was studying hormone-naive women, and that is not the majority of the population buying compounded estrogen face cream or repurposing an existing prescription in 2026. Nobody has studied combined exposure for a woman on a systemic patch, gel, or pill — the same women now being asked in comment sections whether they can apply their EstroGel or Divigel to their face instead of the arm or thigh where it is actually studied and dosed.

For an outside check on this reading, Selfority reviewed Dr. Jen Gunter's coverage of the same trend on The Vajenda. Her reporting flags the same core problems:

• A lack of data supporting effectiveness
• Lack of safety data
• Telehealth platforms using the consult as a bait-and-switch to upsell compounded estrogen face cream as an add-on

A newer study is circulating that backs a branded face cream sold directly to menopausal women. It doesn't close this gap either. Ninety participants, three arms, double-blind, placebo-controlled, twelve weeks, reviewed by an institutional review board — on paper, a step up from most of what came before it.

It is not, however,  independently peer-reviewed or published in a journal anywhere Selfority could find. It lives on the company's own site and in a rotating cast of influencer and affiliate blog posts. The company runs and funds it, chooses which numbers to publish, and reports the results through its own marketing team rather than an outside review process. That doesn't make the findings false. What it does mean is that this is a company's account of its own product rather than a peer-reviewed trial. The same combined-exposure question remains unanswered.

The sales pitch is nearly a hundred years old

This isn't a new idea, and the version circulating now isn't even a particularly novel one. It's a claim that has been rerunning, with new packaging, since 1927.

The first version wasn't even estrogen.

1927: Amor Skin, a glandular extract from turtles or lizards, was packaged in a reproduction Pompeian lamp and priced at what would run several hundred dollars today. The pitch was a turtle's regenerative power, transferred to the face. The only evidence was an ad claiming physicians had endorsed it.

1936: Real estrogenic creams are introduced when factory workers filling ampoules of injectable hormones noticed the backs of their hands looked younger after months of incidental oil exposure. No trial. No control group. A noticed thing became a product, and within a year a cream called Endocreme had made oestrogenic face cream a real force on drugstore shelves.

The product snowballed. The regulatory bar the FDA eventually set had nothing to do with whether the creams worked — only whether anyone could prove, after the fact, that a specific concentration had hurt someone. Manufacturers read that as an invitation. One popular cream shipped at five times the agency's informal safety limit and wasn't pulled until lab samples confirmed it years later. Another was seized outright at fifteen times the limit; the company's fix was to dilute the formula and keep selling. Efficacy was never the test. Harm was, and only once it was already on someone's face. That pattern has worrisome echoes in today's unregulated supplement marketplace.

1961: Revlon found a loophole that has shaped category advertising. The company sold a version of the cream built with a hormone precursor rather than actual estrogen. The ad copy specifically avoided the word hormone: "no hormone activity, no hormone effects," promising only that skin would look smoother. It worked.

Europe banned hormone cosmetics while American manufacturers quietly rebranded into gentler language — precursor compounds, plant sterols, and eventually the phrase still on ingredient lists today, "bioidentical."¹

See an Interactive Timeline of The Hormone Cream Era

The packaging changed to survive scrutiny, again and again, for decades, while the underlying evidence never closed the gap behind it. That is the same pattern shows up in 2026 estrogen cosmetic marketing.

This is what the underlying biology supports

Estrogen receptors sit throughout the skin, not just in reproductive tissue, and the collagen loss that comes with declining estrogen is well established — and steep. Women lose roughly 30 percent of their dermal collagen in the first five years after menopause, then continue losing about two percent a year after that. That rapid fade is one reason why many women believe that their face changes practically overnight in their late 40s or early 50s.

On skincare blogs, supplement pitches, and even company research reports, the 30 percent figure gets attributed to a single 1987 study by Brincat in Obstetrics & Gynecology. In fact, the data in that study reports a flatter average of 1 to 2 percent a year. The 30-percent figure comes from a 2005 review Brincat wrote in Climacteric that synthesizes other research and moves this widely cited figure even further from the original measurement.

Collagen loss is real and it makes perfect sense to consider whether restoring some estrogen locally might soften it. That is exactly why a trend built around a prescription hormone spreads as fast as it does — and why careful, informed women who would never touch an unregulated supplement are trying this without a second thought. Where the claim falls apart is not the biology. It is what happens the moment the studies are asked to actually back up what's being sold — just as it did in 1927, 1936, and 1961.

In February 2026, the FDA removed the black box warning from estrogen therapies including topical vaginal estrogen, after concluding the old warning overstated the risk relative to the evidence. That (overdue) shift applies to approved doses, routes, and application sites. It says nothing new about applying any of it to the face.

The bottom line and what you should keep in mind

It is understandable if you're tired of being told to accept what's happening to you face as you age. It makes sense that estrogen cream sounds more credentialed than something you find in a beauty or wellness aisle.

The lack of lab evidence is the problem. 

A narrowly designed, three-decade-old trial with a zero patient-reported outcomes have been flattened into "studies show estrogen cream reduces wrinkles." The statement excludes criteria and sample sizes. Nonetheless, it's sold by influencers and via a handful of small, mostly uncontrolled or company-run trials that make it look like an established treatment.

This is the same substitution that's been running since Amor Skin arrived in a Pompeian lamp: a plausible-sounding mechanism standing in for actual proof, dressed in whatever language a given decade finds most convincing. Turtle glands. Hormone twins. No hormone activity, no hormone effects. Bioidentical. Estrogen is estrogen.

Different words, same gap.

Selfority's guidance is straightforward: vaginal estrogen belongs where it is approved and studied — the tissue it is prescribed for, at the dose it is dosed for. Until a real safety and efficacy profile exists for facial use, applying it there isn't evidence-backed skincare; it's a marketing claim borrowing credibility from a real prescription. That standard applies to any product recommended without the evidence to support it. If the evidence changes, this guidance will too.

A hundred years is a long time to wait for someone to finally run that trial — and until it's run, the right place for that conversation is with your own doctor, who can weigh it against your specific prescription and history.

¹ Sourcing note: this historical account draws on an archive of period marketing and regulatory records shared by cosmetic chemist Kelly Dobos, a contributor to the Unbiased Science research community.